2024.11.14 MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver MN-001patents
2024.05.28 MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions MN-001academic conference
2024.03.20 MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society MN-001
2023.08.15 MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe MN-001patents
2023.08.14 MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe MN-001NASH/NAFLDpatents
2023.04.30 MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada MN-001patents
2023.01.10 MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada MN-001patents
2023.01.09 MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil MN-001patents
2022.12.06 MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation MN-001
2022.09.13 MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada MN-001
2022.08.09 MediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation MN-001
2022.07.27 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea MN-001
2022.07.26 MediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia MN-001NASH/NAFLD
2022.06.23 MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan MN-001joint research
2022.04.11 MediciNova Announces Plans for a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia MN-001NASH/NAFLD
2022.03.17 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Korea MN-001NASH/NAFLDpatents
2022.02.01 MediciNova Receives a New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Korea MN-001patents
2022.01.31 MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Canada MN-001patents
2022.01.26 MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Europe MN-001patents
2021.11.12 MediciNova Announces MN-001 (tipelukast) Data regarding Lipid Metabolism in NASH/NAFLD to be Presented at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases MN-001NASH/NAFLDacademic conference
2021.10.21 MediciNova Announces Abstract regarding the Mechanism by which MN-001 (tipelukast) Alters Triglyceride Metabolism Accepted for Presentation at the 19th International Symposium on Atherosclerosis (ISA2021) MN-001academic conference
2021.09.01 MediciNova Announces MN-001 (tipelukast) Abstract regarding Lipid Metabolism in NASH/NAFLD Accepted for Presentation at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases MN-001NASH/NAFLDacademic conference
2020.11.13 MediciNova Announces Presentation of Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model at The Liver Meeting Digital Experience™ 2020 MN-001academic conference
2020.10.13 MediciNova Announces Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model to be Presented at The Liver Meeting Digital Experience™ 2020 MN-001academic conference
2020.06.24 MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Europe MN-001patents
2020.02.18 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Japan MN-001NASH/NAFLDpatents
2020.01.28 MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in Europe FibrosisMN-001patents
2019.10.23 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of NAFLD and NASH in Japan MN-001NASH/NAFLDpatents
2019.10.08 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Idiopathic Pulmonary Fibrosis in Japan FibrosisMN-001patents
2019.10.01 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in China FibrosisMN-001patents
2019.07.31 MediciNova Announces MN-001 Research Collaboration with the National Cerebral and Cardiovascular Disease Research Center in Japan MN-001joint research
2018.04.13 国際肝臓会議2018/第53回欧州連合肝臓研究会年次総会におけるMN-001のNASH/NAFLDを適応とするフェーズ2臨床治験の中間解析に関するポジティブデータ発表のお知らせ MN-001NASH/NAFLDacademic conference
2018.04.02 MN-001の高中性脂肪血症を伴うNASH /NAFLDを適応とするフェーズ2臨床治験の早期終了のお知らせ － 中間解析における極めて良好な結果を踏まえて－ MN-001NASH/NAFLDclinical trials
2018.01.29 国際肝臓会議 2018/第 53 回欧州連合肝臓研究会年次総会における MN-001 の NASH /NAFLD を適応とするフェーズ 2 臨床治験に関する演題発表採択のお知らせ MN-001NASH/NAFLDacademic conference
2015.07.27 高中性脂肪血症を伴うNASH患者を対象とするMN-001のフェーズ2臨床治験プロトコルに対するFDAの承認通知受領のお知らせ MN-001NASH/NAFLDclinical trials
2015.02.25 MN-001の進行型NASHを適応とするフェーズ2臨床治験に関してアメリカ肝臓病学会･製薬産業協議会の協賛学会での発表のお知らせ MN-001NASH/NAFLDacademic conference
